SYK · Stryker Corp
$330.69
+8.57 (+2.66%)
At close · Aug 28
Market Cap
$127.12B
Shares
383.57M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$25.12B
+11.2%
FY2025
Net Income
$3.25B
+8.5%
FY2025
Gross Margin
63.96%
0pp
FY2025
Operating Margin
19.47%
+3.1pp
FY2025
Diluted EPS
$8.40
+8.2%
FY2025
Operating Cash Flow
$5.04B
+18.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $25.84B | $25.12B | $22.6B | $20.5B | $18.45B | $17.11B | $14.35B | $14.88B | $13.6B | $12.44B | $11.33B | $9.95B | $9.68B | $9.02B | $8.66B | $8.31B | $7.32B | $6.72B | $6.72B | $6B | |
| — | $9.05B | $9.05B | $8.16B | $7.44B | $6.87B | $6.14B | $5.29B | $5.19B | $4.66B | $4.26B | $3.82B | $3.34B | $3.32B | $3B | $2.78B | $2.81B | $2.29B | $2.18B | $2.13B | $1.87B | |
| — | $16.79B | $16.07B | $14.44B | $13.06B | $11.58B | $10.97B | $9.06B | $9.7B | $8.94B | $8.18B | $7.5B | $6.6B | $6.36B | $6.02B | $5.88B | $5.5B | $5.03B | $4.54B | $4.59B | $4.14B | |
| — | — | 63.96% | 63.91% | 63.7% | 62.76% | 64.11% | 63.11% | 65.14% | 65.72% | 65.73% | 66.26% | 66.38% | 65.7% | 66.72% | 67.88% | 66.16% | 68.77% | 67.51% | 68.27% | 68.92% | |
| — | $1.66B | $1.62B | $1.47B | $1.39B | $1.45B | $1.24B | $984M | $971M | $862M | $787M | $715M | $625M | $614M | $536M | $471M | $462M | $394M | $336M | $367.8M | $375.3M | |
| — | $8.78B | $8.65B | $7.69B | $7.11B | $6.39B | $6.43B | $5.36B | $5.36B | $5.1B | $4.55B | $4.14B | $3.61B | $3.55B | $3.47B | $3.37B | $3.15B | $2.71B | $2.51B | $2.63B | $2.39B | |
| — | $733M | $732M | $623M | $635M | $627M | $619M | $472M | $464M | $417M | $371M | $319M | $210M | $188M | $138M | $123M | $122M | $58M | $36M | $40M | $41.4M | |
| — | $1.62B | $1.57B | $1.43B | $1.34B | $1.28B | $1.27B | $1.08B | $1.04B | $966M | $859M | $752M | $590M | $586M | $511M | $486M | $481M | $410M | $385M | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | $50M | $75M | $76M | — | $67M | $34.9M | $0 | |
| — | $11.25B | $11.18B | $10.75B | $9.17B | $8.74B | $8.38B | $6.83B | $6.98B | $6.4B | $5.88B | $5.33B | $4.74B | $5.11B | $4.76B | $4.14B | $3.81B | $3.28B | $2.95B | $3.07B | $2.83B | |
| — | $5.53B | $4.89B | $3.69B | $3.89B | $2.84B | $2.58B | $2.22B | $2.71B | $2.54B | $2.3B | $2.18B | $1.86B | $1.25B | $1.26B | $1.74B | $1.69B | $1.75B | $1.59B | $1.52B | $1.31B | |
| — | — | 19.47% | 16.33% | 18.97% | 15.4% | 15.1% | 15.49% | 18.23% | 18.65% | 18.46% | 19.21% | 18.71% | 12.88% | 13.92% | 20.11% | 20.3% | 23.92% | 23.71% | 22.61% | 21.79% | |
| — | $7.16B | $6.46B | $5.12B | $5.23B | $4.12B | $3.86B | $3.3B | $3.76B | $3.5B | $3.16B | $2.93B | $2.45B | $1.83B | $1.77B | $2.23B | $2.17B | $2.16B | $1.98B | — | — | |
| — | — | $607M | $409M | $363M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $214M | $232M | $212M | $148M | -$158M | -$303M | -$269M | -$151M | -$181M | -$234M | -$254M | -$126M | -$86M | -$44M | -$36M | — | -$22M | $30M | $61.2M | $62.8M | |
| — | $5.15B | $4.51B | $3.49B | $3.67B | $2.68B | $2.28B | $1.95B | $2.56B | $2.36B | $2.06B | $1.92B | $1.74B | $1.16B | $1.21B | $1.71B | $1.69B | $1.73B | $1.62B | $1.58B | $1.37B | |
| — | $1.42B | $1.27B | $499M | $508M | $325M | $287M | $355M | $479M | -$1.2B | $1.04B | $274M | $296M | $645M | $206M | $407M | $341M | $456M | $517M | $432.4M | $383.4M | |
| — | $3.73B | $3.25B | $2.99B | $3.17B | $2.36B | $1.99B | $1.6B | $2.08B | $3.55B | $1.02B | $1.65B | $1.44B | $515M | $1.01B | $1.3B | $1.35B | $1.27B | $1.11B | $1.15B | $1.02B | |
| — | — | 12.92% | 13.25% | 15.44% | 12.78% | 11.66% | 11.14% | 13.99% | 26.12% | 8.2% | 14.54% | 14.47% | 5.32% | 11.15% | 14.99% | 16.19% | 17.39% | 16.47% | 17.08% | 16.96% | |
| — | $3.92B | $2.85B | $3.12B | $2.97B | $2.67B | $2.62B | $1.05B | $2.11B | $3.48B | $1.23B | $1.53B | $1.05B | $29M | $1.11B | $1.28B | $1.34B | $1.17B | $1.2B | $1.05B | $1.19B | |
| USD/shares | — | $9.73 | $8.49 | $7.86 | $8.34 | $6.23 | $5.29 | $4.26 | $5.57 | $9.50 | $2.73 | $4.40 | $3.82 | $1.36 | $2.66 | $3.41 | $3.48 | $3.21 | $2.79 | $2.81 | $2.48 |
| USD/shares | $14.95 – $15.10* | $9.65 | $8.40G | $7.76 | $8.25G | $6.17G | $5.21 | $4.20 | $5.48 | $9.34 | $2.68 | $4.35 | $3.78 | $1.34 | $2.63 | $3.39 | $3.45 | $3.19 | $2.77 | $2.78 | $2.44 |
| shares | — | — | 382.2M | 381M | 379.6M | 378.2M | 377M | 375.5M | 374M | 374.1M | 374M | 374.1M | 376.6M | 378.5M | 378.6M | 380.6M | 386.5M | 396.4M | 397.4M | 408.1M | — |
| shares | — | — | 386.5M | 385.6M | 383.7M | 382.2M | 382.3M | 380.3M | 379.9M | 380.3M | 380.1M | 378.5M | 380.9M | 382.8M | 382.1M | 383M | 389.5M | 399.5M | 399.4M | 413.6M | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2007–FY2025: $4.12B in buybacks, $11.84B in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 3.73×
EV/EBIT
—
Peer median 20.71×
P/E (TTM)
34.34×
Peer median 26.99×
Peer medians compare against the 8 similar-size Medical Devices companies (of 139 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| MedSurg and Neurotechnology | $15,647,000,000 | $13,518,000,000 | $12,163,000,000 | $10,893,000,000 | $9,538,000,000 | $8,345,000,000 | $8,475,000,000 | — |
| Orthopaedics and Spine | $9,469,000,000 | $9,077,000,000 | $8,335,000,000 | $7,556,000,000 | $7,570,000,000 | $6,006,000,000 | $6,409,000,000 | — |
| Orthopaedics | $9,469,000,000 | $9,077,000,000 | $8,335,000,000 | $7,556,000,000 | — | $4,959,000,000 | $5,252,000,000 | $4,991,000,000 |
| Medsurg | — | — | — | — | — | $6,400,000,000 | $6,492,000,000 | $6,045,000,000 |
| Neurotechnology and Spine | — | — | — | — | — | $2,992,000,000 | $3,140,000,000 | $2,565,000,000 |
| Reconstructive | — | — | — | — | — | $4,959,000,000 | $5,252,000,000 | $4,991,000,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| United States | $19,006,000,000 | $16,943,000,000 | $15,257,000,000 | $13,638,000,000 | $12,321,000,000 | $10,455,000,000 | $10,957,000,000 | $9,848,000,000 |
| EMEA | $3,181,000,000 | $2,897,000,000 | $2,618,000,000 | $2,348,000,000 | $2,299,000,000 | $1,818,000,000 | $1,888,000,000 | $1,793,000,000 |
| Asia Pacific | $2,164,000,000 | $2,020,000,000 | $1,946,000,000 | $1,885,000,000 | $1,973,000,000 | $1,630,000,000 | $1,617,000,000 | $1,532,000,000 |
| Other Foreign Countries | $765,000,000 | $735,000,000 | $677,000,000 | $578,000,000 | $515,000,000 | $448,000,000 | $422,000,000 | $428,000,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Medical | $4,204,000,000 | — | — | — | — | — | $4,528,000,000 | $2,118,000,000 |
| Trauma and Extremities | $3,948,000,000 | — | — | — | — | $3,444,000,000 | $3,278,000,000 | $1,580,000,000 |
| Endoscopy | $3,807,000,000 | — | — | — | — | $3,526,000,000 | — | $1,846,000,000 |
| Instruments | $3,183,000,000 | — | — | — | — | — | — | $1,822,000,000 |
| Knees | $2,656,000,000 | — | — | — | — | $3,134,000,000 | — | $1,701,000,000 |
| Neuro Cranial | $2,485,000,000 | — | — | — | — | — | — | — |
| Neurovascular | $1,968,000,000 | — | — | — | — | $973,000,000 | $924,000,000 | — |
| Hips | $1,865,000,000 | — | — | — | — | — | $2,766,000,000 | $1,336,000,000 |
| Other Orthopaedics | $815,000,000 | — | — | — | — | $714,000,000 | $701,000,000 | — |
| Spine | $185,000,000 | — | — | — | — | $2,094,000,000 | — | $828,000,000 |
| Neuro Cranial Interventional Spine | — | $413,000,000 | $327,000,000 | $282,000,000 | — | — | — | — |
| Neurotechnology | — | — | — | — | — | — | $1,983,000,000 | $1,737,000,000 |
| Other Med Surg And Neurotechnology | — | — | $343,000,000 | $302,000,000 | $277,000,000 | — | — | — |
| Other Orthopaedics Domain | — | — | — | — | — | $464,000,000 | $415,000,000 | $374,000,000 |
| Other Orthopedics Enabling Technologies | — | $152,000,000 | $149,000,000 | $131,000,000 | — | — | — | — |
| Sustainability | — | — | — | — | — | — | $286,000,000 | $259,000,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| MedSurg and Neurotechnology | $4,672,000,000 | $4,004,000,000 | $3,470,000,000 | $2,831,000,000 | $2,807,000,000 | $2,414,000,000 | $2,304,000,000 | — |
| Orthopaedics | $2,820,000,000 | $2,591,000,000 | $2,265,000,000 | $2,202,000,000 | — | — | — | — |
| Medsurg | — | — | — | — | — | $1,837,000,000 | $1,642,000,000 | $1,444,000,000 |
| Neurotechnology and Spine | — | — | — | — | — | $647,000,000 | $839,000,000 | $700,000,000 |
| Orthopaedics and Spine | — | — | $2,399,000,000 | $2,296,000,000 | $2,180,000,000 | $1,588,000,000 | $2,084,000,000 | — |
| Reconstructive | — | — | — | — | — | $1,518,000,000 | $1,907,000,000 | $1,804,000,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| MedSurg and Neurotechnology | 29.9% | 29.6% | 28.5% | 26% | 29.4% | 28.9% | 27.2% | — |
| Orthopaedics and Spine | — | — | 28.8% | 30.4% | 28.8% | 26.4% | 32.5% | — |
| Orthopaedics | 29.8% | 28.5% | 27.2% | 29.1% | — | — | — | — |
| Medsurg | — | — | — | — | — | 28.7% | 25.3% | 23.9% |
| Neurotechnology and Spine | — | — | — | — | — | 21.6% | 26.7% | 27.3% |
| Reconstructive | — | — | — | — | — | 30.6% | 36.3% | 36.1% |
Key facts
CIK
310764
CUSIP
863667101
13F (30d)
1406 filings
1349 filers
Visit website
Investor relations